In our study, we developed a pro-Canakinumab, which can be selectively reactivated at the inflammatory site of RA that expresses high levels of MMP-9 (Supplementary Figure S2), and may locally and specifically neutralize IL-1β in the disease region, thereby preventing systemic on-target toxicities. This evidence concerns the gene IL1B and rheumatoid arthritis.